Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Pembrolizumab in Combination With Standard 1st Line Therapy (Lenvatinib / Chemotherapy) for Locally Advanced or Metastatic Poorly Differentiated or Anaplastic Thyroid Cancer

NCT04731740 is registered in ClinicalTrials.gov with Saint Petersburg State University, Russia as lead sponsor.

NCT NCT04731740
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04731740 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Pembrolizumab in Combination With Standard 1st Line Therapy (Lenvatinib / Chemotherapy) for Locally Advanced or Metastatic Poorly Differentiated or Anaplastic Thyroid Cancer
Lead sponsor
Saint Petersburg State University, Russia
Phase
Phase 2
Overall status
Withdrawn
Start date
December 28, 2020
Completion date
December 28, 2023
Enrollment
0 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

metastatic thyroid gland carcinoma, poorly differentiated thyroid gland carcinoma, thyroid gland anaplastic carcinoma by ajcc v8 stage